To test this hypothesis, we treated OI mice with Tocilizumab (T), a monoclonal antibody that targets IL-6 signaling by competing for IL-6R (Figure 4A) or with a quimeric anti-TNF protein, etanercept (Enbrel®) (Figure S3A). Here, IL6 is linked to osteogenesis imperfecta.